Full-Time
Clinical-stage biopharma developing biparatopic nanobodies
$280k - $315k/yr
San Carlos, CA, USA
In Person
In-office at least 4 days per week; relocation to San Carlos, California if required.
MD
See people who can refer or advise you
Preparing company summary.
Company Size
51-200
Company Stage
IPO
Headquarters
Fremont, California
Founded
2023
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Relocation Assistance
Attovia Therapeutics, a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases, priced its upsized initial public offering at $17.00 per share. The San Carlos-based company will sell 17,000,000 shares, generating gross proceeds of $289.0 million before underwriting costs and expenses. Attovia has also granted underwriters a 30-day option to purchase up to 2,550,000 additional shares at the offering price. The company's common stock is expected to begin trading on the Nasdaq Global Market on 5 August 2026 under the ticker symbol "ATTO", with the offering closing on 6 August 2026. Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets are serving as joint book-running managers, whilst LifeSci Capital acts as passive book-running manager.
Attovia Therapeutics has disclosed that Venbio Global Strategic Fund IV and Goldman Sachs-affiliated entities each hold 5% or greater stakes in the company. This follows Attovia's oversubscribed $105 million Series B financing round, led by Goldman Sachs Alternatives with participation from venBio and other investors. Since launching in June 2023, Attovia has raised $165 million in total. The Series B proceeds will advance lead programmes ATTO-1310 and ATTO-002 through initial clinical readouts and further develop its ATTOBODY platform. Goldman Sachs Alternatives appointed Colin Walsh to Attovia's board of directors. VenBio has been a consistent investor since Attovia's inception. The increased ownership reflects investor confidence in Attovia's pipeline and proprietary platform for developing bi-specific therapeutics targeting immune-mediated diseases.
Attovia Therapeutics, a San Carlos, CA-based privately-held, clinical-stage biopharma company, raised $90M in Series C funding
Attovia Therapeutics announced a $90 million Series C financing led by Deep Track Capital, with participation from new and existing investors. The funds will advance clinical studies for ATTO-1310 in chronic pruritus and ATTO-3712 in atopic dermatitis, and expand their pipeline of multi-specific therapeutic candidates. Rebecca Luse from Deep Track Capital will join the Board of Directors. The financing supports Attovia's goal of achieving clinical proof-of-concept for its lead assets.
The Bay Area–based biotech plans to use the funds to advance two lead programs, one to treat atopic dermatitis and another for immune-mediated diseases.